The QualityStocks Daily Thursday, May 30th, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (ONVO) +103.36%

QualityStocks (TURA) +45.00%

PoliticsAndMyPortfolio (RNWR) +39.82%

The QualityStocks Daily Stock List

PharmaCielo Ltd. (PHCEF)

Small Cap Power, Stock Twits, New Cannabis Ventures, Market Screener, InvestorsHub, Stocks News Feed, Stockhouse, PR Newswire, Trading View, Stock Target Advisor, Baystreet, National Institute for Cannabis Investors, and Technical420 reported previously on PharmaCielo Ltd. (PHCEF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PharmaCielo Ltd. is the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. PharmaCielo is a global company with a concentration on ethical and sustainable processing and supplying of all-natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. The Company lists on the OTC Markets has its corporate office in Toronto, Ontario.

PharmaCielo's principal, and wholly-owned subsidiary, PharmaCielo Colombia Holdings S.A.S., is headquartered at its nursery and propagation center in Rionegro, Colombia. PharmaCielo is the first company to hold Colombian licences for cannabis with unrestricted percentages of tetrahydrocannabinol (THC) and cannabidiol (CBD). This makes it the world’s largest licensed producer (LP).

PharmaCielo’s facility features 12.1 hectares (1.3 million square feet) of open-air greenhouses ready for cultivation. It will supply plant seedlings to more than 1,000 hectares (2,500 acres) of contract growers’ open-air greenhouses for final cultivation. PharmaCielo is working on the construction and commercial commissioning of a downstream processing facility. The Company’s aim is to begin commercial sales in the first half of this year.

PharmaCielo recently announced that its Colombian subsidiary received from the national cultivar registry approval for the listing of a further 10 strains. Each has a prominent tetrahydrocannabinol (THC) profile. The additional registration of the new strains to the national cultivar registry, including a unique 1:1 THC to CBD ratio strain, doubles the number of approved strains PharmaCielo holds in the registry. This makes it the largest holder of approved strains in Colombia. Furthermore, it paves the way for the commercial registration, production and sale of the 20 unique strains.

PharmaCielo announced this past January that it formed an equity joint venture (JV) with Mino Labs S.A. de C.V. Mino Labs is a specialty pharmaceutical company and medical supply distributor based in Mexico. This JV is to bring medicinal cannabis oil to Mexico.

Yesterday, PharmaCielo announced that it has enlisted former U.S. Congressman and long-time medical cannabis advocate Mr. Dana Rohrabacher as a special advisor to the Company. Mr. Rohrabacher began his political career as President Ronald Reagan's special assistant and speechwriter. He was elected as a U.S. Representative from the State of California District 42 in 1988. He served in Congress for almost thirty years. Rep. Rohrabacher is a well-known advocate for the legalization of medical cannabis and protection of medical cannabis patients' rights.

PharmaCielo Ltd. (PHCEF), closed Thursday's trading session at $5.11, down 0.97%, on 26,746 volume. The average volume for the last 3 months is 64,828 and the stock's 52-week low/high is $4.51/$9.975.

chart

Assure Holdings Corp. (ARHH)

NetworkNewsWire, StreetWise Reports, Stockhouse, StockScores, OTC Dynamics, InvestorX, OTC Markets, Stockwatch, Wallet Investor and Barchart reported previously on Assure Holdings Corp. (ARHH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Assure Holdings Corp. is a provider of intraoperative neuromonitoring (IONM) services. The Company works with neurosurgeons and orthopedic spine surgeons to provide a turnkey set of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure Holdings’ shares trade on the OTC Markets Group’s OTCQB. The Company has its corporate office in Denver, Colorado.

Surgical procedures that involve the nervous system, directly, indirectly or inherently places neural structures at risk. The integrity of those structures at risk can be monitored using different techniques. These techniques are known as intraoperative neurophysiologic monitoring, or IONM. The goal of IONM is to identify changes in brain, spinal cord, and/or peripheral nerve function. This is to prevent complications that could result in irreversible nerve damage.

Common surgical procedures include neurological surgery, orthopedic surgery, otolaryngology surgery, cardiovascular surgery, and cardiothoracic surgery. IONM may also be used for any surgery that potentially may place the nervous system at risk. Assure has a highly skilled staff that is capable of covering cases ranging from spinal cord monitoring to complicated intracranial brain function mapping.

Assure Holdings concentrates mainly on supporting spinal and vascular surgeries. The Company has plans in place to support other classes of medicine, which rely on the standard of care that intraoperative neuromonitoring provides. Assure employs its own staff of technologists. In addition, it uses its own state-of-the-art monitoring equipment, handles 100 percent of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided.

Today, Assure Holdings announced that it acquired Littleton Professional Reading, LLC. Littleton is a professional IONM company headquartered outside of Denver. Assure Holdings purchased Littleton Professional Reading for $700,000. This includes more than $2.5 million of accounts receivable.

Littleton Professional Reading managed roughly 375 spine and neurosurgery cases in 2018. This purchase will be funded with cash on hand and will be payable in three equal installments over the next six months. The transaction closed on May 29, 2019.

Assure Holdings Corp. (ARHH), closed Thursday's trading session at $1.34, up 5.27%, on 22,379 volume. The average volume for the last 3 months is 6,392 and the stock's 52-week low/high is $1.07/$2.65.

chart

Khiron Life Sciences Corp. (KHRNF)

NetworkNewsWire, Midas Letter, Micro Small Cap, Investor Ideas, Wallmine, Stockhouse, Proactive Investors, Investing News, Wallet Investor, Dividend Investor, New Cannabis Ventures, Market Screener, Pot Stock News, PR Newswire, Financial Content, GlobeNewswire, InvestorsHub, Virtual Investor Conferences, and Insider Financial reported beforehand on Khiron Life Sciences Corp. (KHRNF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Khiron Life Sciences Corp. is an integrated cannabis company with core operations in Latin America. The Company is fully licensed in Latin America for the cultivation, production, domestic distribution, and international export of THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. Established in 2017 and OTCQB-listed, Khiron Life Sciences is headquartered in Toronto, Ontario.

In May of 2018, Khiron Life Sciences listed on the TSX Venture Exchange. As a result, it became one of the first Colombian based medical cannabis companies to trade on any exchange worldwide. The Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to boost prescription and brand loyalty to address priority medical conditions in the Latin American market. This includes chronic pain, epilepsy, depression, as well as anxiety.

Khiron provides investor exposure to the rapidly legalizing cannabis markets in Latin America. The Company is leveraging its technical capabilities and agricultural advantages to secure a competitive position in global markets.

Khiron has operations in three countries in Latin America (Colombia, Chile and Uruguay). Its core operations are in Colombia. Khiron’s capacity to export THC and CBD extracts (medicinal from Colombia) and dry flower (from Uruguay), allows it to take advantage of low-cost cultivation to engage in the $140 billion European market. Distribution channels of branded products include medical products distribution by way of wholly-owned clinics and wellness Latin American and U.S. retail distribution.

Recent Khiron Life Sciences highlights include the Company closing a $28.75 Million bought deal equity financing. Khiron also signed a Letter of Intent (LOI) to establish a medical cannabis distribution agreement for more than 900 pharmacies in Colombia.

Furthermore, the Company signed a distribution agreement for its Kuida® cosmeceutical brand with Cafam, which is a foremost Colombian drugstore chain. Khiron is also expanding to Europe. It signed a non-binding agreement to acquire Italy-based Canapalife Group.

Today, Khiron Life Sciences announced that Khiron President Chris Naprawa will present live at VirtualInvestorConferences.com on Tuesday, June 4, 2019. The presentation will be at 12:30 PM Eastern Time (https://tinyurl.com/June4CannabisVIC).

Khiron Life Sciences Corp. (KHRNF), closed Thursday's trading session at $2.00, down 2.44%, on 210,599 volume. The average volume for the last 3 months is 315,333 and the stock's 52-week low/high is $0.664/$3.28.

chart

Gulf Keystone Petroleum Limited (GUKYF)

Value Forum, Stock Digest, Trading View, Whale Wisdom, Real Investment Advice, Investors Hangout, 4-Traders, Market Screener, Pink Investing, Dividend Investor, Equity Clock, Stockhouse and Wallet Investor reported previously on Gulf Keystone Petroleum Limited (GUKYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gulf Keystone Petroleum Limited is a top independent operator and producer in the Kurdistan Region of Iraq. The Company is the operator of the Shaikan oil field with present production capacity of 40,000 barrels of oil per day. Gulf Keystone Petroleum has a premier track record of demonstrated drilling and operating successes in the Kurdistan region of Iraq. OTCQX-listed, the Company has its head office in Hamilton, Bermuda.

Gulf Keystone Petroleum International Ltd. (GKPI) is a wholly-owned subsidiary of Gulf Keystone Petroleum. GKPI holds an interest in the Shaikan Block Production Sharing Contract (PSC), where it is also the operator. On August 6, 2009, Gulf Keystone announced a major discovery with the Shaikan-1 exploration well. In August of 2012, the Company declared Shaikan a commercial discovery. In June of 2013, the Shaikan Field Development Plan was approved.

The Shaikan block, operated by Gulf Keystone, is approximately 60 km to the north-west of Erbil encompassing an area of 283 km². The Production Sharing Contract (PSC) for the Shaikan block was awarded in November of 2007.

Gulf Keystone Petroleum’s strategy is to move to the large-scale staged development of the Shaikan field. The phased development approach to the implementation of the Shaikan Field Development Plan will enable the Company to attain a considerable ramp up of production. It will do so while ensuring Gulf Keystone retains flexibility in the development of this large field. It will bring the Company closer to the goal of fully financing its operating and development activities from production cash flows. A component of Gulf Keystone’s near-term strategy is to maintain production from Shaikan production facilities at 40,000 bopd, with a view to increasing to 55,000 bopd, and further beyond.

In July of 2015, Gulf Keystone started trucking Shaikan crude oil a distance of 120 km to Fishkhabour on the Turkish border for injection into the export pipeline to Ceyhan in Turkey. During July 2018, the tie-in of the 400m spur pipeline from PF-2 to the Atrush export pipeline system was completed. All production from PF-2 (c.14,500 bopd) is now undergoing export through this pipeline.

At present, oil from PF-1 is being trucked to the DNO facility at Fishkhabour for export through Turkey. Gulf Keystone has agreed to terms for the installation of a 16 kilometer pipeline from PF-1 into the export pipeline system. Work has begun on the project. The Company’s expectation is that completion will be mid-2019. This would result in all of Shaikan's production being exported by pipeline and the elimination of the trucking of crude oil. This would provide cost savings and HSSE benefits. On April 26, 2019, Gulf Keystone confirmed that a gross payment of $14.7 million ($11.5 million net to Gulf Keystone Petroleum) was received from the Kurdistan Regional Government for Shaikan crude oil sales during January 2019.

Gulf Keystone Petroleum Limited (GUKYF), closed Thursday's trading session at $2.96, up 3.50%, on 415 volume. The average volume for the last 3 months is 1,133 and the stock's 52-week low/high is $2.05/$3.98.

chart

Viemed Healthcare, Inc. (VIEMF)

Penny Stock Tweets, TipRanks, Connecting Investor, Stockhouse, Stockwatch, Stock Target Advisor, Wallet Investor, 4-Traders, Invest Tribune, and Barchart reported earlier on Viemed Healthcare, Inc. (VIEMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Viemed Healthcare, Inc. provides home respiratory service to patients struggling with different respiratory diseases. These include chronic obstructive pulmonary disease (COPD) and various neuromuscular diseases. The Company, by way of its subsidiaries, provides in-home health care solutions in the U.S. Viemed Healthcare is based in Lafayette, Louisiana.

Originally called Sleep Management, the Company started offering non-invasive ventilation (NIV) therapy in 2012. In 2014, it rebranded to become Viemed Healthcare. Viemed Healthcare uses best in class technology and equipment to increase quality of life in the homes of patients with respiratory diseases.

The Company has a highly effective home treatment model. It focuses on transitional care, education, personalized care plans, as well as chronic disease management. Viemed is the largest independent specialized provider of non-invasive ventilation (NIV) in the U.S. home respiratory health care industry.

The Company’s Respiratory Care Therapists deliver therapy, education and counseling to patients in their home using the most effective technology available. Viemed’s Patient Care Coordinators work with hospitals, ACO’s, SNF’s and other referral sources to simplify the transitioning of patients from hospital to home. This achieves better management of length of stay and re-admission rates to hospitals.

Viemed Healthcare’s COPD Management Program is called “PARCC”. It is the most effective, patient-centric therapy available for hypercapnic patients. This has allowed the Company to become the largest independent non-invasive ventilation therapy provider in the country and the only organization of its type with a Pulmonologist on staff.

Viemed Healthcare provides respiratory services and related equipment, including non-invasive ventilators, positive airway pressure machines, and oxygen units. The Company also provides services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services.

Moreover, it provides in-home sleep apnea testing to ascertain the existence of sleep apnea at home. Furthermore, Viemed leases equipment, including non-invasive ventilators, BiPaP and CPaP devices, percussion vests, and other respiratory equipment, and also sells medical equipment and/or patient medical services. In addition, the Company provides therapy, education, and counseling to patients in their homes using technology.

For Q1 2019, Viemed Healthcare grew its ventilator patient count by about 36 percent versus the prior year’s comparable quarter and 8 percent over Q4 2018. Mr. Casey Hoyt, Viemed Healthcare Chief Executive Officer, said, “We have started the year fast with our growth outpacing prior year’s first quarter growth rate as we continue to get our therapy on more patients and expand into more geographic areas.”

Viemed Healthcare, Inc. (VIEMF), closed Thursday's trading session at $7.226, up 3.52%, on 8,542 volume. The average volume for the last 3 months is 9,692 and the stock's 52-week low/high is $2.85/$7.80..

chart

Bimini Capital Management, Inc. (BMNM)

TipRanks, Zacks, Stockwatch, Proactive Investors, OTC Markets, InvestorsHub, Last10k, Dividend Investor, 4-Traders, Stockhouse, Investor Guide, Marketbeat, and Simply Wall St reported earlier on Bimini Capital Management, Inc. (BMNM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bimini Capital Management, Inc., via its subsidiaries, engages in the asset management business in the U.S. It operates through two segments, Asset Management and Investment Portfolio. The Company invests mainly in, but is not limited to investing in, residential mortgage-related securities issued by the Federal National Mortgage Association (Fannie Mae), the Federal Home Loan Mortgage Corporation (Freddie Mac) and the Government National Mortgage Association (Ginnie Mae). OTCQB-listed, Bimini Capital Management is based in Vero Beach, Florida.

By way of its wholly-owned subsidiary, Bimini Advisors Holdings, LLC, Bimini Capital Management serves as the external manager of Orchid Island Capital, Inc. Orchid Island Capital is a publicly-traded Real Estate Investment Trust – REIT, (NYSE: ORC). Orchid is managed to earn returns on the spread between the yield on its assets and its costs. This includes the interest expense on the funds it borrows.

As Orchid’s external manager, Bimini Advisors Holdings receives management fees and expense reimbursements for managing Orchid's investment portfolio and daily operations. Bimini Advisors provides Orchid with its management team, including its officers, along with appropriate support personnel.

Furthermore, Bimini Capital Management manages the portfolio of its wholly-owned subsidiary, Royal Palm Capital, LLC. Royal Palm is managed with an investment strategy alike to that of Orchid Island Capital.

Recently, Bimini Capital Management announced results of operations for the three month period ended March 31, 2019. It reported Net Income of $1.6 million (or $0.13 per common share). The results for the quarter included Advisory Services Revenue of $1.6 million, Interest and Dividend Income of $2.6 million, Interest Expense of $1.7 million, Net Realized and Unrealized Gains of $1.4 million, Operating Expenses of $1.6 million and an Income Tax Provision of $0.6 million.

Yesterday, Bimini Capital Management commenced a Tender Offer to purchase up to $2.2 Million in value of shares of its Class A Common Stock. The Offer is made upon the terms and subject to the conditions described in the Offer to Purchase and in the related Letter of Transmittal that are being filed by Bimini Capital Management with the U.S. Securities and Exchange Commission (SEC) on May 29, 2019 and are being sent to holders of Class A Common Stock or designated brokers or other nominees, as applicable.

                   

Bimini Capital Management, Inc. (BMNM), closed Thursday's trading session at $1.91, up 24.84%, on 295,299 volume. The average volume for the last 3 months is 4,085 and the stock's 52-week low/high is $1.50/$2.69.

chart

Exactus, Inc. (EXDI)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, InvestorsHub, Barchart, Morningstar, Proactive Investors, Marketbeat, Trading View, 4-Traders, OTC Presswire, Zacks, Investors Hangout, Stockopedia, Market Screener, YCharts, Wallet Investor, Stockwatch, and MarketWatch reported previously on Exactus, Inc. (EXDI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Exactus, Inc. is a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products. Additionally, the Company is developing point of care diagnostics. Exactus sells its CBD products direct to consumers through its Hemp Healthy® brand. It also sells white label products to third-party resellers. Exactus is based in Delray Beach, Florida.

The Company also engages in producing industrial hemp from farms in Oregon. Its plan is to extract and manufacture directly through cGMP facilities. Exactus One World is the name of the Exactus farming and production program.

With the acquisition of Hemp Healthy, Exactus’ plan is to introduce and launch additional CBD products in 2019. The Company states that Hemp Healthy will continue to serve as an information resource and leader in the CBD market place through setting the industry standards on transparency and quality with every product. The Hemp Healthy platform also offers a sales affiliate program for medical professionals and social influencers.

Exactus entered into a Master Product Development and Supply Agreement with Ceed2Med this past January. Ceed2Med utilizes cGMP facilities and with the Agreement, Exactus has been allotted a minimum of 50 and up to 300 kilograms per month, and up to 2,500 kilograms annually, of active phyto-cannabinoid (CBD) rich ingredients for resale.

Exactus offers tinctures, edibles, capsules, and topical solution products manufactured for use by Ceed2Med. Ceed2Med is an international sourcing and distribution platform for industrial hemp and industrial hemp-derived products.

Exactus is intensifying its efforts to lead the industry in the hemp-derived Cannabidiol (CBD) market with its initial planting of seedlings in roughly 200 prime acres in southwest Oregon on its Exactus One World (EOW) farms this month. Exactus reported the arrival of an independent fairness opinion from Scalar, LLC highlighting EOW’s estimated enterprise value between about $55 million and $74 million. EOW is planting an assortment of genetics. It expects to yield thousands of pounds of hemp and top-quality flower per acre.

Exactus will be presenting at the 9th Annual LD Micro Invitational on June 4, 2019 at 10 AM PST/1PM EST at the Luxe Sunset Bel Air Hotel in Los Angeles, California. Mr. Phil Young, Exactus Chief Executive Officer, will be presenting and meeting with investors throughout the day.

Exactus, Inc. (EXDI), closed Thursday's trading session at $0.86, down 4.44%, on 40,891 volume. The average volume for the last 3 months is 12,051 and the stock's 52-week low/high is $0.048/$4.00.

chart

Rhino Resource Partners LP (RHNO)

Zacks, MarketWatch, Mining Connection, GlobeNewswire, Annual Reports, TopPennyStockMovers, Marketbeat, Simply Wall St, 4-Traders, Dividend Channel, Wall Street Mover, and PCG Advisory reported earlier on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Rhino Resource Partners LP is a diversified energy limited partnership. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in numerous basins in the U.S.  Rhino Resource Partners has its head office in Lexington, Kentucky.

The Company, through acquisitions and other coal lease transactions, has substantially increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, Rhino has successfully increased its coal production by way of internal development projects. 
 
The Company produces metallurgical and steam coal in an array of basins across the U.S. as well as leases coal. Rhino’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino produces steam coal used to produce electricity and metallurgical coal used in the steel-making process. In addition, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region that provides added cash flows to its business.  
 
In Central Appalachia, approximately 72 percent of its full-year 2019 thermal and met coal production has been contracted at increased prices in comparison to 2018. Rhino’s Pennyrile, Castle Valley and Hopedale operations are considerably sold out for 2019 at prices that are above the Company’s 2018 levels. Moreover, Rhino has executed long-term contracts with different utility customers for thermal coal for 2020 at Pennyrile and Castle Valley.

Recently, Rhino Resource Partners announced its financial and operating results for the quarter ended December 31, 2018. For the quarter, the Partnership reported a Net Loss of $5.6 million and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $6.3 million, versus a Net Loss of $18.7 million and Adjusted EBITDA of $6.7 million in Q4 of 2017.

Diluted Net Loss Per Common Unit was $0.49 for the quarter versus Diluted Net Loss Per Common Unit of $1.45 for Q4 of 2017. Total Revenues for the quarter were $64.7 million, with coal sales producing $63.9 million of the total, versus Total Revenues of $55.8 million and coal revenues of $55.4 million in the fourth quarter of 2017.

Rhino Resource Partners LP (RHNO), closed Thursday's trading session at $0.91165, up 7.10%, on 104 volume. The average volume for the last 3 months is 1,341 and the stock's 52-week low/high is $0.80/$2.00.

chart

Barfresh Food Group, Inc. (BRFH)

Greenbackers, RedChip, Marketbeat, SmallCapVoice, Lions of Wall Street, OTC Journal, Barchart, The Wall Street Transcript, SmallCap Network, and Wall Street Resources reported earlier on Barfresh Food Group, Inc. (BRFH), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Barfresh Food Group, Inc. is a manufacturer and distributor of unique, frozen, ready-to-blend beverages. These include smoothies, shakes, and frappes. These products are primarily for restaurant chains and the foodservice industry. Barfresh Food Group and Barfresh Food Group Pty Ltd. in Australia (Barfresh Australia) are under common control. Barfresh Food Group is headquartered in Beverly Hills, California.

Barfresh acquired the exclusive worldwide patent rights to its ready-to-blend beverage packs. This is on top of its presently held patent rights in the United States and Canada. The Company acquired the intellectual property (IP) for its creative “ready to blend” ingredient packs for North America.

Barfresh Food Group has approval to sell its products into all branches of the U.S. Armed Forces. This covers bases around the world that are home to 1.3 million active troops. Barfresh has entered into agreements expanding to a host of military locations.  

Barfresh’s proprietary, patented system uses portion-controlled pre-packaged beverage ingredients. These deliver freshly made smoothies that are quick, cost efficient, and without waste.

The innovative system combines all the ingredients of a quality smoothie into an individually pre-portioned pack. The pack contains real fruit pieces, low fat frozen yogurt or sorbet, fruit juice, and ice. These are subsequently blended with water to create a smoothie.

In late January 2019, Barfresh Food Group announced that it has approvals for 100 locations across numerous branches of the military throughout the U.S. It expects all locations to be installed and pouring within the next 60 days (as of the end of January).

Mr. Riccardo Delle Coste, Barfresh Food Group's Chief Executive Officer, stated, "We now have over 100 locations compared to no military locations this time last year. Growth in the military channel is only one of the reasons we expect to achieve very strong top line growth in 2019.  We continue to see strong progress in the education channel, and we also will be rolling out multiple products in a leading national restaurant chain with over 2,500 locations in 2019.”

Recently, Barfresh Food Group announced that it raised more than $4.3 million of capital via a private placement of equity and cash exercise of existing warrants. The Company completed this capital raise to accelerate growth.

Barfresh Food Group, Inc. (BRFH), closed Thursday's trading session at $0.50, up 4.17%, on 223,500 volume. The average volume for the last 3 months is 98,101 and the stock's 52-week low/high is $0.379/$0.81.

chart

Prophecy Development Corp. (PRPCF)

InvestorIntel, The StreetWise Reports, Barchart, 4-Traders, InvestorsHub, Business Wire, Marketwired, Wallmine, GuruFocus, Wallet Investor, Junior Mining Network, OTC Markets, Stockhouse, Uptick Newswire, and Trading View reported previously on Prophecy Development Corp. (PRPCF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Prophecy Development Corp. engages in the acquisition, exploration, and development of mineral and energy projects. The Company’s primary goal is to develop the Gibellini primary vanadium mining project in the Battle Mountain region in northeastern Nevada to production. The design of the Gibellini vanadium project is to be an open pit, heap leach operation. Gibellini is the most advanced primary vanadium deposit in the U.S. Prophecy Development has its corporate office in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQX.

In June of last year, Prophecy Development announced the filing of a technical report prepared in accordance with National Instrument 43-101, Standards of Disclosure for Mineral Projects (NI 43-101) concerning a Preliminary Economic Assessment (PEA) for the Company’s Gibellini vanadium project in Eureka, Nevada. This project is about 25 miles south of the town of Eureka.

The PEA reported an after-tax cumulative cash flow of $601.5 million, an Internal Rate of Return (IRR) of 50.8 percent, a Net Present Value (NPV) of $338.3 million at a 7 percent discount rate and a 1.72 years payback on investment from start-up assuming an average vanadium pentoxide price (V2O5) of $12.73 per pound.

Furthermore, Prophecy Development has its Titan (Titanium Vanadium) Project. This Project is at Flett and Angus Townships, 120 kilometers northeast of Sudbury, Ontario. The Property comprises 262 contiguous hectares consisting of 17 patented claims.

Moreover, the Company has its Pulacayo (Silver-Zinc-Lead) project. This Project is in Bolivia, 107 km northeast of Sumitomo Corporation’s San Cristobal silver mine; 185 km southwest of Coeur Mining, Inc.’s San Bartolome silver mine; and 139 km north of Pan American Silver Corp.’s San Vicente silver mine.

Recently, Prophecy Development announced that it has retained Amec Foster Wheeler E&C Services, Inc. (Wood) to undertake updating of the mineral resource and mining section for Prophecy’s forthcoming Feasibility Study (FS) to be completed to the standards of National Instrument 43-101 (NI 43-101) for its Gibellini vanadium project in Nevada. The expectation is that the FS will be completed by year end 2019.

Prophecy Development also recently announced the appointment of Mr. Michael Doolin as its Chief Operating Officer (COO) and interim Chief Executive Officer (CEO), effective April 1, 2019. In this role, Mr. Doolin will manage the Company’s global operations while collaborating with Prophecy's Executive Chairman, Mr. John Lee, on investor marketing, fundraising and Prophecy's overall strategic direction.

Mr. Doolin is a mining professional. He has more than three decades of operational and management experience in Nevada with a concentration on planning and budgeting.

Prophecy Development Corp. (PRPCF), closed Thursday's trading session at $0.12, down 2.38%, on 78,350 volume. The average volume for the last 3 months is 111,673 and the stock's 52-week low/high is $0.086/$2.299.

chart

Innovative Food Holdings, Inc. (IVFH)

MissionIR, Penny Stock Tweets, Investors Hangout, Dividend Investor, Plunkett Research, Marketbeat, Equity Clock, StockInvest, Simply Wall St, Tip Ranks, Stockopedia, YCharts, The Bowser Report,  Stock Guru, FeedBlitz, Capital Cube, and Wallet Investor reported earlier on Innovative Food Holdings, Inc. (IVFH),  and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Innovative Food Holdings, Inc. is an industry leading specialty food platform. The Company, by way of its subsidiaries, is a foremost nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal foods, to the professional foodservice market. Perishable product is delivered direct to the Company’s kitchen the next day via overnight delivery. Non-perishable product is delivered direct to customers. Innovative Food Holdings is headquartered in Bonita Springs, Florida.

For Chefs (Chef Direct), the Company’s vertically-integrated platform enables it to source 7,000-plus specialty foods worldwide and deliver within 24-72 hours. Innovative Food Holdings’ subsidiaries include Artisan Specialty Foods and Innovative Gourmet.

Artisan Specialty Foods is a nationwide specialty food distributer, re-packer, and importer. Artisan serves hundreds of customers in the Chicago area. In addition, Artisan serves as a nationwide fulfillment center for other Company subsidiaries operating in the foodservice and direct-to-consumer markets.

Innovative Food Holdings supplies chefs with innovative, organic, sustainable, and artisanal products sourced from all areas globally. The Company markets its  products directly to the consumer, through its website at www.forthegourmet.com.

Innovative Food Holdings’ subsidiary, Innovative Gourmet, acquired substantially all the assets of one of North America’s leading online gourmet food and gift retailers in 2018. The business operates under igourmet’s valued and trusted trade name.

igourmet offers a broad assortment of high quality gourmet and specialty food products via www.igourmet.com, and through a complete line of omnichannel partners. Furthermore, igourmet offers a wide array of specialty food products to restaurants, specialty retailers and other business establishments through its specialty foodservice division.

Pertaining to Innovative Food Holdings’ customer service, the Company has dedicated Chef Advisors that are available by phone or email to assist customers. They provide assistance with additional product information, sourcing additional gourmet products, and menu consultation. They also provide assistance with application and complementing product suggestions and providing more specific delivery window estimates.

Innovative Food Holdings, Inc. (IVFH), closed Thursday's trading session at $0.57, up 3.64%, on 77,207 volume. The average volume for the last 3 months is 52,074 and the stock's 52-week low/high is $0.415/$0.805.

chart

Lion One Metals Limited (LOMLF)

Stock Twits, Investors Hub, Junior Mining Network, MarketWatch, Morningstar, Top Stocks, Barchart, Stockhouse, OTC Markets, Canadian Mining Report, Investor Ideas, StreetWise Reports, TradingView, Mining Atlas, and Stock World reported previously on Lion One Metals Limited (LOMLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lion One Metals Limited focuses on advancing to production at its 100 percent owned and fully permitted high grade underground Tuvatu Gold Project. Tuvatu is situated on the island of Viti Levu in the Republic of Fiji. Tuvatu is the largest undeveloped gold project in Fiji. Moreover, it is one of the highest-grade gold projects anywhere in the world. Lion One Metals is headquartered in Vancouver, British Columbia. In addition, the OTCQX-listed Company has offices in Fremantle, Australia and in Waimalika, Nadi, Republic of Fiji.

Lion One Metals is focused on building production of 100,000 oz. per year over 10 years. The Company holds a 200 km² exploration license package encompassing the entire Navilawa volcano, with the Tuvatu mining lease at its center.

Lion One Metals is centering on cost effective and environmentally responsible construction, development, and advancement of Tuvatu towards production. This is tied with exploration of its district-scale license areas covering the highly prospective and underexplored Navilawa volcano. It is advancing Tuvatu as a near-term production opportunity with exploration upside in the southwest Pacific Ring of Fire.

The Company has modeled Tuvatu for exploration after regional giants in the low sulphidation family of high grade epithermal gold deposits. This includes Porgera and Lihir in Papua New Guinea, and Vatukoula in Fiji, which boast production of over 35 million ounces of gold in similar alkaline volcanic settings.

The independent Tuvatu NI 43-101 PEA technical report by Mr. Ian Taylor, BSc (Hons) MAusIMM (QP) dated June 1, 2015 foresees a low cost underground gold mining operation producing 352,931 ounces of gold over 7 years at head grades of 11.30 g/t Au, and cash costs of US$567 per ounce with all-in sustaining cost (AISC) of US$779 per ounce.

Lion One Metals has not based a production decision on a Feasibility Study (FS) of mineral reserves demonstrating economic and technical viability. Thus, there is increased uncertainty and economic and technical risks associated.

Recently, Lion One Metals announced a partnership with Swiss-based clean energy provider the meeco Group to construct and install a hybrid solar/diesel power plant for the Company's 100 percent owned and fully permitted Tuvatu Gold Project. Lion One Metals will be a 50 percent shareholder of a Special Project Vehicle (SPV) by way of an agreed buy-in structure.

Lion One Metals will use meeco's 7 MW peak "sun2live" solar power generation system paired with diesel generators. This is to generate up to 11 MW peak power production providing a continuous 24-hour source of power for the Tuvatu gold mine and processing plant.

Lion One Metals announced at the beginning of this month that Dr. Quinton Hennigh was appointed as Technical Advisor for the Company's Tuvatu Gold Project in Fiji. Dr. Hennigh is an internationally-renown economic geologist, with more than 25 years of exploration experience and expertise with major gold mining companies.

Lion One Metals Limited (LOMLF), closed Thursday's trading session at $0.52619, up 3.68%, on 201,678 volume. The average volume for the last 3 months is 40,128 and the stock's 52-week low/high is $0.244/$0.599.

chart

Leading Edge Materials Corp. (LEMIF)

InvestorsHub, MarketWatch, Stockhouse, Metals Channel, 4-Traders, Investing News, Penny Stock Tweets, Wall Street Analyzer, Metals News, Market Screener, and Investor Place reported earlier on Leading Edge Materials Corp. (LEMIF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Leading Edge Materials Corp. concentrates on the production of high value critical raw materials for the European market. It has an operating base in the Nordic region. The Company’s flagship asset is the Woxna Graphite production facility in central Sweden targeting the supply of specialty materials for lithium ion battery production. OTCQB-listed, Leading Edge Materials is based in Vancouver, British Columbia.

The Company operates in four divisions: Graphite, Lithium, Rare Earth and Cobalt. Leading Edge’s assets and research focus are towards the raw materials for Li-ion batteries (graphite, lithium, cobalt); materials for high thermal efficiency building products (graphite, silica, nepheline); and materials that improve the efficiency of energy generation (dysprosium, neodymium, hafnium). Its investments are linked to the global shift to low-carbon energy generation and energy storage.

Leading Edge Materials has 100 percent ownership of industry-leading assets in the Nordic region. It has 100 percent ownership of graphite, cobalt, lithium and rare earth element deposits across three mining supportive jurisdictions. In addition, the Company has a unique position in the sustainable supply of critical materials for the high growth lithium ion battery market.

Leading Edge Materials has its Romanian Exploration Alliance. The Exploration Alliance is focused on the discovery and development of lithium ion battery raw materials. The main efforts of the Exploration Alliance as of early November 2018, was directed towards cobalt mineralization within the Upper Cretaceous Carpathian magmatic belt of the Balkan region.

In January, Leading Edge Materials provided a summary of test work conducted on graphite from its 100 percent owned Woxna mine in Sweden during last year. With the test program complete, the Company is now moving ahead to an engineering study supporting the installation of a Battery Graphite Demonstration Plant at the Woxna site. The demonstration plant, when installed, will enable process conditions to be optimized and larger volumes of natural graphite anode material to be supplied to prospective lithium ion battery customers.

Leading Edge Materials is advancing a portfolio of European battery raw material projects. These include the fully built and permitted above-mentioned Woxna graphite mine in Sweden, the Bihor Sud cobalt-copper-nickel project in Romania, and the Norra Kärr heavy rare earth element-zirconium-hafnium deposit. All are high merit projects within the European raw material sector.

The Company’s internal corporate Strategic Review firstly highlighted that Leading Edge's combination of discovery-stage and development-stage assets may present different requirements concerning operational structure, capital needs and investor preferences. The Board resolved that the next stage of the Strategic Review will identify and compare opportunities for the Woxna graphite mine.

Potential recommendations from this stage of the Strategic Review may include a transition to a freestanding European company. Additionally, it will consider direct third-party investment into Woxna, horizontal or vertical joint-venture of with aligned parties, or a standalone public listing of Woxna on a Swedish exchange. The Board cautions that there is no assurance or guarantee that any potential transaction identified by the Strategic Review will be pursued.

Leading Edge Materials Corp. (LEMIF), closed Thursday's trading session at $0.1848, up 9.74%, on 1,084,695 volume. The average volume for the last 3 months is 112,698 and the stock's 52-week low/high is $0.072/$0.547.

chart

Chemesis International, Inc. (CADMF)

Green Stock Report, Financial Buzz, Insider Financial, Stockhouse, otc.watch, The Street, InvestorsHub, Connecting Investor, Wallmine, Midas Letter, Investing News, MarketWatch, Cannabindex, CannabisFN, Business Insider, Nasdaq.com, Dividend Investor, GuruFocus, YCharts, Morningstar, Seeking Alpha, Market Screener, and Trading View reported on Chemesis International, Inc. (CADMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Chemesis International, Inc. is a vertically integrated worldwide leader in the cannabis industry that lists on the OTC Markets Group’s OTCQB. The Company has facilities in Puerto Rico and California. Chemesis takes advantage of exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products. Chemesis International has its corporate headquarters in Vancouver, British Columbia.

The Company operates in the most important and most profitable sectors of the cannabis industry. It is positioned for fast growth in the developing fully-licensed and fully-compliant cannabis industry. Chemesis will grow new markets and revenues within Cultivation, Manufacturing, Distribution and Retail Sales. The Company is presently retailing exclusive products in Puerto Rico and actively engaging retail storefronts in the California marketplace.

At present, Chemesis International has operations underway in Puerto Rico with Natural Ventures, Colombia with La Finca, as well as California with California Sap and Desert Zen. Its state-of-the-art grow facility in Puerto Rico showcases a 2,000-plus grow light capacity and a 30,000-plus lb overall grow capacity.

La Finca brings greater than 1,000 acres of land for cultivation in Colombia. Chemesis has more than 2,000 relationships with farming families, which consist of its land package. Moreover, Desert Zen has emerged as a fully compliant first mover in California. Desert Zen has a fleet of fully compliant vehicles that are servicing California.

Chemesis International is working to open exclusively branded shops in numerous markets. The Company distributes and transports California Sap, Jay and Silent Bob’s Private Stash, and also third party brands to more than 600 dispensaries in California and Puerto Rico.

Recently, Chemesis International announced plans to add an additional 25,000 ft2 of manufacturing, in Cathedral City, California. With the recent commercialization of its fully compliant state-of-the-art extraction facility, Chemesis is moving ahead with the expansion plan and expects completion of the additional manufacturing space by Q2 2019. This facility will be full State compliant for manufacturing, packaging, distribution and transportation. This will allow for products to be distributed directly to State licensed dispensaries.

Also recently, Chemesis International announced that its subsidiary, Natural Ventures, signed a definitive agreement for an annual purchase order of a minimum total of USD $4,000,000. The Company will cultivate, manufacture, package and distribute for the Puerto Rico based dispensary network from its fully licensed, state compliant facility. The products are white labeled under the dispensaries brand and delivered on a weekly basis. Natural Ventures commenced fulfilling purchase orders in February 2019. It is providing the vendor with edibles, vaporizers, lotions, beverages, and flower.

Chemesis International, Inc. (CADMF), closed Thursday's trading session at $1.34, up 14.78%, on 264,251 volume. The average volume for the last 3 months is 206,315 and the stock's 52-week low/high is $0.20/$1.72.

chart

The QualityStocks Company Corner

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: ZRRRF).

National cannabis holding company IONIC Brands (CSE: IONC) (OTC: ZRRRF), formerly Zara Resources Inc., on Wednesday announced that it has entered into a Letter of Intent (“LOI”) to acquire British heritage brand Astleys of London HK Limited. To view the full press release, visit: http://nnw.fm/D9Adf.

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC's product lines are pioneering the changing landscape of cannabis consumption. The company's refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC's Certified Clean program verifies that every product leaving the company's facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green's technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package's QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company's flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC's immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC's expansion and development into Washington state's leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck's.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC's aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the "Top 50 Companies to Work for in Cannabis" by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: ZRRRF), closed the day's trading session at $0.3351, up 4.65%, on 130,598 volume. The average volume for the last 3 months is 271,322 and the stock's 52-week low/high is $0.0359/$0.635.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) comments on the recent changes to South Africa's Medicines and Related Substances Act. This past week, South Africa's Department of Health removed Cannabidiol ("CBD") from the country's Schedule 7 list of highly controlled drugs, allowing for legal sale of CBD products made in accordance with the government's specified preparations. "This meaningful change to South Africa's legislation creates immense opportunity for Medigrow to manufacture and supply high-quality CBD oil to a neighbouring jurisdiction," said Navdeep Dhaliwal, CEO of Supreme Cannabis. "We are pleased to see countries like South Africa adopting thoughtful changes to policy and implementing well-regulated systems with the potential to improve public health and wellness."

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.25, up 1.12%, on 286,160 volume. The average volume for the last 3 months is 1,322,318 and the stock's 52-week low/high is $1.87/$7.89.

Recent News

chart

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Los Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) today introduces the strategic direction of its wholly owned and operated flagship farm, NUGS Farm North, located in Northern California. The fully operational, six-acre marijuana cultivation operation is expected to reach complete capacity by the fall of 2019, and will position Cannabis Strategic Ventures as one of the largest cultivators in terms of volume in the state of California. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how “the demand for CBD products is exploding - at the moment the demand is far outpacing the supply,” as Heather Darby recently said. Darby is a hemp expert at the University of Vermont Extension who has advised agricultural officials and prospective hemp cultivators in Massachusetts. Furthermore, the company was highlighted in the Venture Breakfast Bits, by 24/7 Market News.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed the day's trading session at $1.08, up 6.76%, on 15,780 volume. The average volume for the last 3 months is 61,093 and the stock's 52-week low/high is $0.75/$5.94.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands Inc. (TSXV:GYSR) announces that its acquisition target — Solace Management Group Inc. ("Solace") — has unveiled its latest brand, WildTails. Out of the gate, WildTails has developed new product lines with three available SKUs for both dogs and cats, complementing the robust sales of Solace's Apawthecary Pets brand. Also today, NetworkNewsWire released a report on the company detailing how the company’s licensed producer (LP), Apothecary Botanicals, has received Health Canada license amendment approval to update its 7,000-square-foot facility located in Port Coquitlam, British Columbia.

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.70, up 27.27%, on 10,000 volume. The average volume for the last 3 months is 8,345 and the stock's 52-week low/high is $0.55/$0.85.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF) was highlighted today in a publication from Investorideas.com, examining how as the global cannabis markets continue to grow and as the population continues to embrace CBD infused products, it is inevitable that non-cannabis companies with worldwide distribution networks will look to partner with cannabis companies to add CBD infused products to their existing brands.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.3529, up 1.79%, on 260,991 volume. The average volume for the last 3 months is 581,268 and the stock's 52-week low/high is $0.285/$1.129.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering California's MAUCRSA framework, what it means for companies operating in the state, and why TransCanna Holdings Inc. (CSE: TCAN) represents a compelling opportunity. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Voters in Missouri approved a ballot measure which legalized medical marijuana in 2018. In March this year, the Department of Health and Senior Services released draft rules for the medical marijuana program and invited public comment on those rules. Last week, the department completed making changes to the draft rules based on the feedback received and they published the revised draft rules on the department’s website on Friday.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $6.00, even for the day, on 73,872 volume. The average volume for the last 3 months is 160,322 and the stock's 52-week low/high is $0.769/$7.789.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Trxade Group (OTCQB: TRXD), an integrated pharmaceutical services company, today announced that its subsidiary, Community Specialty Pharmacy, has secured its certification with LegitScript. According to the update, with more than 24,000 independent pharmacies in the United States, Google and Facebook mandate that pharmacies must undergo a rigorous application and review process by LegitScript, a third-party compliance organization, in order to advertise on their platforms. To view the full press release, visit: http://nnw.fm/Xa0Ny.

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed the day's trading session at $0.45, even for the day. The average volume for the last 3 months is 2,755 and the stock's 52-week low/high is $0.23/$1.00.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) was featured today in the 420 with CNW by CannabisNewsWire. Voters in Missouri approved a ballot measure which legalized medical marijuana in 2018. In March this year, the Department of Health and Senior Services released draft rules for the medical marijuana program and invited public comment on those rules. Last week, the department completed making changes to the draft rules based on the feedback received and they published the revised draft rules on the department’s website on Friday.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.022, even for the day, on 250 volume. The average volume for the last 3 months is 419 and the stock's 52-week low/high is $0.0099/$0.0289.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (OTCQB: ENDV)develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $0.0119, even for the day, on 1,558,582 volume. The average volume for the last 3 months is 2,560,361 and the stock's 52-week low/high is $0.0089/$0.0661.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pursuing several drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://nnw.fm/dIP4x).

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.40, off by 0.76%, on 4,220 volume. The average volume for the last 3 months is 17,765 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce, further to its news release of February 6, 2019, that it will effect on June 3, 2019 (the "Distribution Date") the distribution of unit purchase warrants ("SpinCo Unit Warrants") of TGOD Acquisition Corp. ("SpinCo") to all registered TGOD shareholders of record as of January 31, 2019 (the "Distribution Record Date") who elected to receive the SpinCo Unit Warrants (the "Distribution") under its previously announced plan of arrangement with SpinCo (the "Arrangement"). Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how as products laced with CBD find their way onto the shelves of Sephora, Barney’s, Estee Lauder, and Ulta Beauty, analysts believe the trend could be a significant catalyst. Additionally, the company was highlighted today in the Venture Breakfast Bits, by 24/7 Market News.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.78, off by 4.14%, on 585,838 volume. The average volume for the last 3 months is 1,104,366 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF)today announced a new collaboration with luxury, beauty and wellness icon Joel Warren and his in-house salon at Saks Fifth Avenue’s newly renovated flagship location in New York City. To view the full press release, visit: http://nnw.fm/np3Cw.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.483895, off by 1.25%, on 32,615 volume. The average volume for the last 3 months is 22,625 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Nabis Holdings Inc. formerly Innovative Properties (CSE:NAB) (OTC: INNPF) (FRA: 71P) (“Nabis” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that it has completed the previously announced purchase of certain assets from PDT Technologies LLC (“PDT”), including extraction and production equipment and rights to lease its current production facility in Port Townsend, WA. The purchase includes the exclusive licensing rights to Chong’s Choice brand products throughout the state of Washington.

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.4582, off by 1.08%, on 85,276 volume. The average volume for the last 3 months is 183,736 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed the day's trading session at $0.17, off by 9.33%, on 2,500 volume. The average volume for the last 3 months is 22,460 and the stock's 52-week low/high is $0.15/$0.3944.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.